BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF(V600E)) metastatic colorectal cancer (mCRC) Meeting Abstract
| Authors: | Kopetz, S.; Grothey, A.; Yaeger, R.; Ciardiello, F.; Desai, J.; Kim, T. W.; Maughan, T.; Van Cutsem, E.; Wasan, H. S.; Yoshino, T.; Edwards, M. L.; Golden, A.; Gollerkeri, A.; Tabernero, J. |
| Abstract Title: | BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF(V600E)) metastatic colorectal cancer (mCRC) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120306246 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.TPS3619 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS3619 -- Source: Wos |
